A detailed history of Alliancebernstein L.P. transactions in Argenx Se stock. As of the latest transaction made, Alliancebernstein L.P. holds 21,614 shares of ARGX stock, worth $12.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,614
Previous 9,416 129.55%
Holding current value
$12.2 Million
Previous $4.05 Million 189.5%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$434.22 - $551.9 $5.3 Million - $6.73 Million
12,198 Added 129.55%
21,614 $11.7 Million
Q2 2024

Aug 14, 2024

BUY
$356.01 - $451.55 $3.12 Million - $3.96 Million
8,766 Added 1348.62%
9,416 $4.05 Million
Q1 2024

May 14, 2024

SELL
$356.95 - $413.29 $2.64 Million - $3.06 Million
-7,407 Reduced 91.93%
650 $255,000
Q4 2023

Feb 14, 2024

SELL
$338.91 - $506.01 $2.42 Million - $3.62 Million
-7,154 Reduced 47.03%
8,057 $3.07 Million
Q3 2023

Nov 14, 2023

SELL
$369.35 - $548.43 $498,253 - $739,832
-1,349 Reduced 8.15%
15,211 $7.48 Million
Q2 2023

Aug 15, 2023

BUY
$360.14 - $422.58 $2.82 Million - $3.31 Million
7,837 Added 89.84%
16,560 $6.45 Million
Q1 2023

May 15, 2023

SELL
$334.23 - $403.65 $604,622 - $730,202
-1,809 Reduced 17.18%
8,723 $3.25 Million
Q4 2022

Feb 14, 2023

SELL
$342.17 - $402.31 $1.28 Million - $1.5 Million
-3,732 Reduced 26.16%
10,532 $3.99 Million
Q3 2022

Nov 15, 2022

SELL
$343.2 - $395.75 $1.41 Million - $1.63 Million
-4,107 Reduced 22.36%
14,264 $5.04 Million
Q2 2022

Aug 15, 2022

BUY
$269.58 - $378.88 $2.38 Million - $3.35 Million
8,847 Added 92.89%
18,371 $6.96 Million
Q1 2022

May 13, 2022

BUY
$254.45 - $351.06 $2.42 Million - $3.34 Million
9,524 New
9,524 $3 Million
Q2 2019

Aug 14, 2019

SELL
$115.0 - $141.58 $1.27 Million - $1.56 Million
-11,000 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$98.85 - $134.59 $1.09 Million - $1.48 Million
11,000 New
11,000 $1.37 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.